Publications by authors named "Svetlana Nikolaevna Kondratenko"
Objectives: To evaluate the role of ABCB1 (C3435T rs1045642, rs1128503, rs2032582, rs4148738), SLCO1B1 T521C rs4149056 genetic polymorphisms in the development of major types of methotrexate (MTX) toxicities and the occurrence of a terminal event (death, relapse) in pediatric АLL.
Methods: The study included 124 patients diagnosed with pediatric ALL. All patients treated according to the protocols of the German BFM group (2002/2009) with high-dose (1,000, 2,000 and 5,000 mg/m) methotrexate.
Predictive modeling of adverse drug reactions to tamoxifen therapy for breast cancer on base of pharmacogenomic testing.
Drug Metab Pers Ther
December 2023
Objectives: The present study investigated the analysis of adverse drug reactions (ADRs) to tamoxifen (TAM) in breast cancer patients in relation to the carriage of genetic polymorphisms of genes encoding enzymes of CYP system and transporters of P-glycoprotein (Pg) and predictive models based on it.
Methods: A total of 120 women with breast cancer taking adjuvant TAM were examined for the gene polymorphisms such as , , , , , and (). Allelic variants were determined using the real-time polymerase chain reaction method.
The Effect of Coenzyme Q10 as a Part of Standard Therapy on Plasma Concentrations of Ubiquinol, Ubiquinone, Total CoQ10 and its Redox State in Patients with Ischemic Heart Disease.
Curr Drug Metab
January 2022
Background: Despite CoQ10 being a powerful antioxidant and its redox state that may characterize the body's antioxidant system, the latter remains unstudied in patients with cardiovascular diseases.
Objective: This prospective case-control study aimed to investigate the concentrations of ubiquinol, ubiquinone, total CoQ10 and its redox state in patients with ischemic heart disease (IHD) and arterial hypertension (AH) during standard therapy and with the additional prescription of CoQ10.
Methods: The study included 54 healthy individuals and 26 patients, who were divided into a control group receiving standard therapy and a test group receiving CoQ10 in addition to standard therapy.